Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
From SciSparc Ltd
Via GlobeNewswire
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
From SciSparc Ltd
Via GlobeNewswire
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
From SciSparc Ltd
Via GlobeNewswire
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
From SciSparc Ltd
Via GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
From SciSparc Ltd
Via GlobeNewswire
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
From SciSparc Ltd
Via GlobeNewswire
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
SciSparc Adopts Limited Duration Shareholder Rights Plan
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
From SciSparc Ltd
Via GlobeNewswire
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
From SciSparc Ltd
Via GlobeNewswire
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC)
Via ACCESSWIRE
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.